IN8bio (NASDAQ:INAB) Reports Continued Progression-Free Survival in Phase 1 Trial at ASH Annual Meeting

IN8bio, Inc., a clinical-stage biopharmaceutical company focusing on innovative gamma-delta T cell therapies, recently shared updated data on December 10, 2024. This data demonstrated sustained progression-free survival in its Phase 1 investigator-sponsored trial of INB-100 allogeneic gamma-delta T cells for leukemias. The announcement was made at the 2024 American Society of Hematology (ASH) Annual Meeting.

The company’s press release outlined remarkable results indicating INB-100’s ability to provide durable complete remissions (CR) without relapses in acute myeloid leukemia (AML) patients, even those with high-risk disease, following a median follow-up of 19.7 months. The data presented at the ASH meeting unveiled the long-term impact of INB-100, showcasing enduring in vivo expansion and persistence of allogeneic gamma-delta T cells up to 365 days post-administration. This persistence marked a significant milestone, representing the first instance of sustained persistence and expansion with an allogeneic cellular therapy.

IN8bio continues to record positive outcomes, with no new deaths or relapses reported as of September 30, 2024. Notably, all AML patients remained in remission through one year, with those in the high-risk cytogenetic AML category sustaining CR for over three years without maintenance therapy.

Furthermore, the data reaffirmed the well-tolerated safety profile of INB-100, with no observed cases of cytokine release syndrome (CRS) or neurotoxicity (ICANS) and minimal mild infections.

Following these encouraging results, the INB-100 trial has been broadened to incorporate additional patients at the recommended Phase 2 dose (RP2D) level. Recruitment of more patients for the expansion cohort is ongoing, with updated data anticipated to be disclosed in the first half of 2025.

The Phase 1 trial data revealed significant allogeneic gamma-delta T cell expansion and persistence in treated patients for the initial year post-treatment. The safety assessment underlined no dose-limiting toxicities, limited grade 1-2 acute graft versus host disease (GvHD), and no treatment-related deaths noted. The continuity of patients in remission, including those surpassing three years post-treatment, was a validation of the therapy’s efficacy.

IN8bio aims to develop gamma-delta T cell-based immunotherapies targeted at cancer patients. Their leading program, INB-100, focuses on AML and evaluates haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant. The company remains steadfast in its commitment to advancing clinical development and achieving anticipated milestones.

Investors and shareholders keen on tracking IN8bio’s progress can refer to their website for more information and updates.

Contact:
Glenn Schulman, PharmD, MPH
Email: [email protected]
IN8bio, Inc.
Patrick McCall
Phone: 646.933.5603
Email: [email protected]

Media Contact:
Kimberly Ha
KKH Advisors
Phone: 917.291.5744
Email: [email protected]

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read IN8bio’s 8K filing here.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.